Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Neuropharmacology
2011 Jan 01;602-3:488-95. doi: 10.1016/j.neuropharm.2010.11.003.
Show Gene links
Show Anatomy links
Ginkgolide B and bilobalide block the pore of the 5-HT₃receptor at a location that overlaps the picrotoxin binding site.
Thompson AJ
,
Jarvis GE
,
Duke RK
,
Johnston GA
,
Lummis SC
.
???displayArticle.abstract???
Extracts from the Ginkgo biloba tree are widely used as herbal medicines, and include bilobalide (BB) and ginkgolides A and B (GA and GB). Here we examine their effects on human 5-HT(3)A and 5-HT(3)AB receptors, and compare these to the effects of the structurally related compounds picrotin (PTN) and picrotoxinin (PXN), the two components of picrotoxin (PTX), a known channel blocker of 5-HT(3), nACh and GABA(A) receptors. The compounds inhibited 5-HT-induced responses of 5-HT(3) receptors expressed in Xenopus oocytes, with IC(50) values of 470 μM (BB), 730 μM (GB), 470 μM (PTN), 11 μM (PXN) and >1mM (GA) in 5-HT(3)A receptors, and 3.1mM (BB), 3.9 mM (GB), 2.7 mM (PTN), 62 μM (PXN) and >1mM (GA) in 5-HT(3)AB receptors. Radioligand binding on receptors expressed in HEK 293 cells showed none of the compounds displaced the specific 5-HT(3) receptor antagonist [(3)H]granisetron, confirming that they do not act at the agonist binding site. Inhibition by GB at 5-HT(3)A receptors is weakly use-dependent, and recovery is activity dependent, indicating channel block. To further probe their site of action at 5-HT(3)A receptors, BB and GB were applied alone or in combination with PXN, and the results fitted to a mathematical model; the data revealed partially overlapping sites of action. We conclude that BB and GB block the channel of the 5-HT(3)A receptor. Thus these compounds have comparable, although less potent, behaviour than at some other Cys-loop receptors, demonstrating their actions are conserved across the family.
Fig. 1. Structures of the compounds used in this study (Panel A), and an alignment of human Cys-loop receptor M2 regions (Panel B). The alignment includes the human 5-HT3 receptor A and B subunits in addition to subunits from other Cys-loop receptors that are inhibited by BB, GB and PTX. M2 residues are usually referred to using prime (′) notation, which is shown below the alignment. Accession numbers for the alignment are: 5-HT3A (P46098), 5-HT3B (O95264), glycine α1 (P23415), glycine β2 (P48167), GABAA α1 (P14867), GABAA β1 (P18505), GABAA γ2 (Q8N1C3).
Fig. 2. BB (panel A), GB (panel B), PXN (panel C) and PTN (panel D) inhibition of the 5-HT3A (filled squares, solid line) and 5-HT3AB (open squares, dotted line) receptor EC50 responses. A inset shows the current rebound sometimes observed following the removal of high concentrations of BB. Panel E shows current-voltage relationships for 5-HT3A receptor responses in the presence of BB, GB, PXN or PTN. The curves have been normalised to the current at measured at −90 mV, and the inset shows the ratios of current amplitudes recorded at +40 mV relative to those at −40 mV. The ratios in the absence of antagonist were unaltered in the presence of BB, GB, PTN or PXN. GA inhibition is not shown as only minimal inhibition was seen at 1 mM in the 5-HT3A receptor only.
Fig. 3. Evidence for channel block. A: The use-dependency observed for GB was absent for BB and PXN. For GB, the percentage inhibition measure at peak (31 ± 3.1%) was less than that measured during the first application (38 ± 0.8%). For GB, full recovery was not seen until a second application of GB was applied (inset); at 0.3 mM GB, the first 5-HT response was 91 ± 2% of the second 5-HT response. B–D: The inhibition observed following the co-application (i) of each compound was not seen if the same compound was pre-applied before 5-HT (ii and iii). When compounds were pre-applied immediately before 5-HT (iii), no reduction in the 5-HT response was noted. 5-HT = 2 μM. BB = 1 mM, GB = 300 μM, PXN = 30 μM. For each compound, traces are representative of >5 experiments on ≥2 batches of oocytes.
Fig. 4. Concentration–response curves in the absence and presence of increasing concentrations of BB and PXN. Increasing the concentration of PXN (Panel A), caused a rightward shift of the concentration-response curves and a change in maximal current that was consistent with non-competitive antagonism. Because of the low potency and poor compound solubility at high concentrations, it was not possible to perform experiments at higher concentrations and observe shifts for BB (Panel B) or GB (data not shown). Because of these limitations, inhibition of the 5-HT3 receptor response was recorded at single compound concentrations, both alone and in combination (seeTable 3).
Ahlemeyer,
Neuroprotective effects of Ginkgo biloba extract.
2003, Pubmed
Ahlemeyer,
Neuroprotective effects of Ginkgo biloba extract.
2003,
Pubmed
Buisson,
Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor.
1998,
Pubmed
Chatterjee,
Structure-activity studies with Ginkgo biloba extract constituents as receptor-gated chloride channel blockers and modulators.
2003,
Pubmed
Chen,
Chromatographic fingerprint analysis for evaluation of Ginkgo biloba products.
2007,
Pubmed
Chen,
Structural model for gamma-aminobutyric acid receptor noncompetitive antagonist binding: widely diverse structures fit the same site.
2006,
Pubmed
Colquhoun,
The quantitative analysis of drug-receptor interactions: a short history.
2006,
Pubmed
Das,
The 5-HT3B subunit confers reduced sensitivity to picrotoxin when co-expressed with the 5-HT3A receptor.
2003,
Pubmed
Das,
Molecular determinants of picrotoxin inhibition of 5-hydroxytryptamine type 3 receptors.
2005,
Pubmed
Deeb,
Direct subunit-dependent multimodal 5-hydroxytryptamine3 receptor antagonism by methadone.
2009,
Pubmed
Erkkila,
Stoichiometric pore mutations of the GABAAR reveal a pattern of hydrogen bonding with picrotoxin.
2008,
Pubmed
Hawthorne,
Molecular determinants of ginkgolide binding in the glycine receptor pore.
2006,
Pubmed
Hawthorne,
A picrotoxin-specific conformational change in the glycine receptor M2-M3 loop.
2005,
Pubmed
Heads,
Structure-activity analysis of ginkgolide binding in the glycine receptor pore.
2008,
Pubmed
Holbrook,
Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function.
2009,
Pubmed
Huang,
Ginkgolides, diterpene trilactones of Ginkgo biloba, as antagonists at recombinant alpha1beta2gamma2L GABAA receptors.
2004,
Pubmed
,
Xenbase
Jaracz,
Ginkgolides and glycine receptors: a structure-activity relationship study.
2004,
Pubmed
Jarboe,
Structural aspects of picrotoxinin action.
1968,
Pubmed
Jensen,
Ginkgolide X is a potent antagonist of anionic Cys-loop receptors with a unique selectivity profile at glycine receptors.
2010,
Pubmed
Kiewert,
Role of GABAergic antagonism in the neuroprotective effects of bilobalide.
2007,
Pubmed
Kondratskaya,
The beta subunit increases the ginkgolide B sensitivity of inhibitory glycine receptors.
2005,
Pubmed
,
Xenbase
Liman,
Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.
1992,
Pubmed
,
Xenbase
Perry,
NOESY on neurotoxins: NMR and conformational assignments of picrotoxins.
2001,
Pubmed
Sasaki,
Bilobalide, a constituent of Ginkgo biloba L., potentiates drug-metabolizing enzyme activities in mice: possible mechanism for anticonvulsant activity against 4-O-methylpyridoxine-induced convulsions.
1997,
Pubmed
Sedelnikova,
Stoichiometry of a pore mutation that abolishes picrotoxin-mediated antagonism of the GABAA receptor.
2006,
Pubmed
,
Xenbase
Smart,
Studies on the mechanism of action of picrotoxinin and other convulsants at the crustacean muscle GABA receptor.
1986,
Pubmed
Thompson,
5-HT3 receptors.
2006,
Pubmed
Thompson,
Antimalarial drugs inhibit human 5-HT(3) and GABA(A) but not GABA(C) receptors.
2008,
Pubmed
,
Xenbase
Thompson,
The antimalarial drugs quinine, chloroquine and mefloquine are antagonists at 5-HT3 receptors.
2007,
Pubmed
,
Xenbase
Ticku,
Binding of [3H]alpha-dihydropicrotoxinin, a gamma-aminobutyric acid synaptic antagonist, to rat brain membranes.
1978,
Pubmed
Xu,
Interaction of picrotoxin with GABAA receptor channel-lining residues probed in cysteine mutants.
1995,
Pubmed
,
Xenbase
Yang,
A proposed structural basis for picrotoxinin and picrotin binding in the glycine receptor pore.
2007,
Pubmed
van Beek,
Ginkgolides and bilobalide: their physical, chromatographic and spectroscopic properties.
2005,
Pubmed
